Welcome to our dedicated page for MICROVISION SEC filings (Ticker: MVIS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on MICROVISION's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into MICROVISION's regulatory disclosures and financial reporting.
MicroVision, Inc. is conducting a primary offering of 6,800,000 shares of common stock together with 6,800,000 Common Warrants, with each share sold with one warrant at a combined public offering price of $2.50. The warrants are immediately exercisable at $2.50 per share and expire five years after issuance. Gross proceeds are expected to be $17.0 million, with estimated net proceeds of approximately $15.6 million after placement fees and expenses, excluding any proceeds from warrant exercises. Shares outstanding will increase from 23,350,027 to 30,150,027 after the offering, before any warrant exercise. MicroVision plans to use the net proceeds for general corporate purposes, including working capital and capital expenditures.
MICROVISION, INC. officer Jeemyung Byun, serving as Chief Commercial Officer, filed an initial statement of beneficial ownership on Form 3. The report lists no equity transactions and shows no holdings or derivative positions in the company’s securities as of the filing.
MicroVision, Inc. is conducting a primary offering of common stock, Pre-Funded Warrants and five-year Common Warrants under its $50,000,000 shelf registration. Each share of common stock (or Pre-Funded Warrant) is sold together with one Common Warrant, with the mix between shares and Pre-Funded Warrants driven by beneficial ownership limits of 4.99% or 9.99% of outstanding stock. The deal is a best-efforts placement through WestPark Capital, which will receive a 6.5% cash fee on gross proceeds and expense reimbursement, and there is no minimum amount required to close. MicroVision plans to use net proceeds for general corporate purposes, including working capital and capital expenditures. The company recently effected a 1-for-15 reverse stock split and reduced authorized common stock to 150,000,000 shares, and has a history of operating losses funded largely through equity and convertible securities. The filing highlights potential dilution, stock-price volatility, lack of a trading market for the Warrants and the absence of any current dividend policy.
MicroVision, Inc. appointed Christine Chambers as Chief Financial Officer and principal financial and accounting officer, effective August 27, 2026. She brings more than two decades of financial leadership across public and high-growth technology companies, including prior CFO roles at Fusemachines, PetMed Express, and RealNetworks.
Her compensation package includes an annual base salary of $425,000, a target annual bonus of 65% of base salary, a one-time new-hire RSU award valued at $1,000,000 vesting over four years, and an annual long-term RSU opportunity valued at $800,000 vesting over three years, all subject to continued employment and equity plan terms. Three months after her start date, she will participate in MicroVision’s Key Executive Severance and Change in Control Plan as a Tier 2 Executive. Interim CFO Stephen Hrynewich will step down from the interim role on the Effective Date but remain in a senior finance role; his transition is stated not to result from any disagreement regarding the company’s operations, policies, or practices.
MicroVision, Inc. reported Q2 2026 revenue of $1,473 thousand, up from $155 thousand a year earlier, driven by IRIS long-range and MOVIA L short-range lidar sensor shipments plus contract and license revenue. Q2 gross profit was $642 thousand.
Operating expenses rose to $24,853 thousand, reflecting higher R&D, acquisition-related costs from the Luminar and Scantinel deals, and restructuring as engineering and manufacturing are consolidated into Orlando. Q2 net loss was $36,943 thousand, and first-half 2026 net loss was $62,237 thousand.
Cash and cash equivalents were $27,208 thousand at June 30, 2026, with net cash used in operating activities of $35,588 thousand in the first half. The company had $27,036 thousand of senior secured convertible notes outstanding and a related $7,050 thousand derivative liability, plus a $380 thousand warrant liability, and access to approximately $41.2 million of remaining at-the-market equity capacity. Management states that high cash burn, increased expenses from the Luminar acquisition, and current liquidity conditions raise substantial doubt about the ability to continue as a going concern through at least twelve months from issuance of these financial statements, despite ongoing financing and cost-reduction plans and a 1-for-15 reverse stock split completed in August 2026.
MicroVision, Inc. reported second quarter 2026 revenue of $1.47 million and a net loss of $36.94 million, or $1.66 per share, compared with revenue of $0.16 million and a net loss of $14.23 million a year earlier. Gross profit turned positive at $0.64 million, but operating expenses of $24.85 million led to a larger operating loss.
For the first half of 2026, revenue was $2.41 million and adjusted EBITDA was a loss of $36.03 million. Cash, cash equivalents and restricted cash totaled $28.87 million as of June 30, 2026, and the company states it has access to $68.4 million of capital, including $41.2 million under an at-the-market facility. Management highlighted a long-term development agreement with a leading construction and mining OEM to integrate its IRIS lidar into autonomous hauling vehicles and ongoing evaluations with customers in AI, e‑commerce logistics, defense and robotics as part of its Lidar 2.0 strategy.
BlackRock, Inc. filed an amended Schedule 13G reporting beneficial ownership of 3,430,821 shares of MicroVision, Inc. common stock, representing 1.0% of the class. BlackRock reports sole voting and dispositive power over all of these shares, with no shared voting or dispositive authority.
The filing notes that various persons have the right to receive dividends or sale proceeds from these shares, but no single person’s interest exceeds five percent of MicroVision’s total outstanding common shares.
MicroVision, Inc. is implementing a 1-for-15 reverse stock split of its common stock, approved by shareholders on July 10, 2026 and confirmed by a Certificate of Amendment filed in Delaware on July 22, 2026. The split becomes effective at 5:00 p.m. Eastern Time on August 1, 2026.
At effectiveness, every fifteen issued and outstanding common shares will be combined into one share, with fractional positions rounded up to the nearest whole share. Authorized capital stock will total 175,000,000 shares, including 150,000,000 common and 25,000,000 preferred; authorized common shares will be reduced from 510 million to 150 million. Outstanding options, warrants, convertible notes and equity plan reserves, and their exercise or conversion prices, will be adjusted proportionately. The stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market under “MVIS” on August 3, 2026, and the reverse split is intended to help satisfy Nasdaq’s minimum bid price requirement.
Smith Jada reported acquisition or exercise transactions in this Form 4 filing.
MicroVision director Jada Smith received an equity grant of 280,152 Restricted Stock Units (RSUs) on 07/16/2026. Each RSU represents a contingent right to receive one share of MicroVision common stock. The RSUs are scheduled to vest in four equal quarterly installments until fully vested on the earlier of the first anniversary of the grant date or the day prior to the issuer's 2027 Annual Meeting of Stockholders, subject to her continued board service. Following this grant, she holds 280,152 RSUs directly.
Schabert Peter reported acquisition or exercise transactions in this Form 4 filing.
MicroVision, Inc. director Peter Schabert received a grant of 280,152 restricted stock units (RSUs) on July 16, 2026. Each RSU represents one share of common stock and will vest in four equal quarterly installments until the earlier of the first anniversary of the grant or the day before the 2027 annual stockholders meeting, contingent on his continued board service.